Diabetes is a major health care problem that has reached crisis proportions. The disease accounts for >14% of total national health care expenditures in the US and untold losses of precious human resources, and new therapies are urgently needed. Although glucose monitoring is central to all therapies for diabetes, present "fingerstick" methods and short-term percutaneous needle-like sensors are objectionable to many potential users, limiting their application. A new, more acceptable glucose sensor is urgently needed that could direct insulin dosing, warn of hypoglycemia, and serve as the missing component of a practical artificial pancreas. We have developed a new, fully implanted glucose sensor and wireless telemetry for long-term implantation in subcutaneous tissues. In studies with normal and diabetic pigs, we have a total of 31 cumulative device-years of implant experience, with 17 of the devices remaining functional for more than one year, and one implant functioning for 520 days (Sci. Trans. Med. 2, 42ra53, 2010). The sensor has also functioned successfully for six months in an initial human trial. The sensor incorporates a unique design in which glucose is monitored via a differential enzyme electrode detection principle that overcomes the limitations of implant encapsulation by the body. This sensor has fundamental advantages over other glucose sensors: users don't need to recalibrate or replace the sensor frequently, making continuous glucose monitoring and potentially the artificial pancreas much more acceptable to the general diabetic public. Although the sensor-telemetry system can function for at least one year and planned improvements may further extend its lifetime, the device will eventually have to be replaced. It is highly desirable to reuse the same implant site i possible, rather than creating multiple new implant sites over a lifetime. The questions to be addressed here are: Can an implant site be reused? What tissue response mechanisms are involved? The hypothesis to be tested is "The implant site is reusuable." Previous studies showed that implant sites have fully stabilized within 8 weeks, indicating that an accelerated 12-week replacement test cycle in the pigs can correspond to a 1 to 2-year clinical replacement cycle. In this Phase I project, four sensor-telemetry units will be implanted in each of two pigs, and weekly glucose challenges will be performed. Devices will be exchanged every 12 weeks, and an extensive statistical analysis will determine whether effective monitoring can continue at the sites. Tissue permeability to glucose and oxygen will be assessed, extensive histologic examination will be performed, and mass transfer models will be constructed. If successful, these studies will provide a foundation for continuous glucose monitoring over a lifetime, with minimal obtrusiveness to people with diabetes.

Public Health Relevance

Glucose monitoring is central to the treatment of diabetes, and there is an urgent need for a generally acceptable glucose sensor. In previous studies, we developed an implantable glucose sensor/telemetry system that can operate for more than one year in animals, but it will eventually need to be replaced. This project will determine if a given implant site can be reused, thereby making continuous glucose sensing minimally obtrusive to people with diabetes, and more acceptable over a person's lifetime.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43DK104296-01
Application #
8823438
Study Section
Special Emphasis Panel (ZDK1-GRB-2 (O3))
Program Officer
Arreaza-Rubin, Guillermo
Project Start
2014-09-24
Project End
2015-08-30
Budget Start
2014-09-24
Budget End
2015-08-30
Support Year
1
Fiscal Year
2014
Total Cost
$225,000
Indirect Cost
Name
Glysens, Inc.
Department
Type
DUNS #
070731646
City
San Diego
State
CA
Country
United States
Zip Code
92121